Help For Adults With ADHD... Coming Soon From Shire

BRIEF SUMMARY of PRESCRIBING INFORMATION
INDICATIONS AND USAGE: Bipolar Manias: SEROQUEL is indicated for the short-term treatment of acute manic episodes associated with bipolar ideorder, as either monotherapy for adjunct therapy to lithium or divelopress. The indicated is will be proposed to see the monotherapy to adjunct therapy that of the proposed is seen and in the seen adjunct therapy that of bepolar i patients initially hospitalized for up to 7 days for acute mana. Effectiveness for more than 3 weeks has not been systematically evaluated in initial trials. Therefore, the physiciant who elects to use SEROQUEL for extended periods should periodically re-evaluate the long-term risks and benefits of the drug for invindrated patient. Schrophyrenia: PSEROQUEL in schrophyrenia was established in short-term (6-week) controlled trials of schrophyrenia repetitions. The effectiveness of SEROQUEL in indicated or the returned of SEROQUEL in schrophyrenia vase established in short-term (6-week) controlled trials of schrophyrenia systematically evaluated in controlled trials. Therefore, the physician who elects to use SEROQUEL for extended periods should periodically re-evaluate the schrop-term use chinary of the drug for the individual patient.

The paper of proposition interest in 1920 and the second control of the paper of th

SEROQUEL® (quetiapine furnarate) Tablets SPENDULLE*** (Queltappine fundament) additional fracts* for the Treatment of Schizophenia and Acute Blooar Mania (monotheniay). Bedy as a Whole Hapotenion (Digitalize Pro). Manifer Schizophenia Mania (monotheniay). Bedy as a Whole Hapotenion (Digitalize Pro). Manifer Schizophin, Volting (Digitalize). A Schizophenia Mania (Manifer). The Company of the Company. Manifer Schizophenia (Manifer) of the Company of

States consistent symmetries. Description (1850).

MDICA BILISE AND DEPHENDENCE: Controlled Substance Classe: SEROULEL is not a controlled substance. Physical and Psychologic dependence: SEROULEL has not been systematically studied, in animals or humans, for its potential for abuse, oberance or physical dependence. While the clinical trials dut not reveal any tendency for any drugs-seaking behavior, these observations were not systematic and its not possible to predict on the basis of this limited experience the extent to which a CNS-state drug will be misused, dwarted, and/or abused once married long-security in the state of carbidy for all states of such patients should be observed obosyly for signs of misuse or abuse of SEROUUEL, e.g., development of tolerance, increases in dose, drugs-session behavior. drug-seeking behavior.

osserved oosely or ogns or misuse or adust or SetHUDUEL, e.g., development or tolerance, increases in dose, of usy-seeking before a misuse or adust of setHUDUEL (quellajone furnantel) in audie overdosage and natalities. In general, reported stops and symptoms were those resulting from an exaggeration of the drugs known pharmacological effects, i.e., drownless and seation, tachycardia and hypotension. One case, involving an estimated overdosa of 96000 mg, was associated with hypotelaems and first degree heart block. In post-marking operations, there have been very rare reports of overdosage, establish and maintain an airway and ensure adequate oxygenation and eventional control of the drugs and ensure adequate oxygenation and eventional control of the considered. The post-mark of the drugs and ensure adequate oxygenation and eventional control of the considered. The post-mark of the drugs of the control of the drugs of the control of the drugs of the control of the drugs of the d

SERCQUEL is a trademark of the AstraZeneca group of companies. © AstraZeneca 2004



SEROQUEL is indicated for the treatment of acute manic episodes associated with bipolar I disorder and the treatment of schizophrenia. Patients should be periodically reassessed to determine the need for continued treatment.

Prescribing should be consistent with the need to minimize the risk of tardive dyskinesia, seizures, and orthostatic hypotension. A rare condition referred to as neuroleptic malignant syndrome (NMS) has been reported with this class of medications, including SEROQUEL.

There have been reports of diabetes mellitus and hyperglycemia-related adverse events associated with the use of atypical antipsychotics, including SEROQUEL.

The most commonly observed adverse events associated with the use of SEROQUEL in clinical trials were somnolence, dry mouth, dizziness, constipation, asthenia, abdominal pain, postural hypotension, pharyngitis, SGPT increase, dyspepsia, and weight gain.





AstraZeneca Pharmaceuticals LP

To prevent medication errors, write "SEROQUEL" clearly on your Rx pad. Spell "SEROQUEL" clearly over the phone.

Redefine Success

www.SEROQUEL.com
Please see Brief Summary of Prescribing Information on following page.